Share

February 2023; 13 (1) Commentary

Practice Current

Variability in Smoking Cessation Intervention Practice Patterns After Ischemic Stroke and Transient Ischemic Attack

Neal S. Parikh, Daniel Restifo, Aravind Ganesh, Hooman Kamel
First published January 17, 2023, DOI: https://doi.org/10.1212/CPJ.0000000000200115
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
41

Share

Article Information

vol. 13 no. 1 e200115
DOI: 
https://doi.org/10.1212/CPJ.0000000000200115
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received April 18, 2022
  • Accepted October 12, 2022
  • First Published January 17, 2023.
Copyright & Usage: 
© 2023 American Academy of Neurology
Other Contributors: 
  • Aravind Ganesh [MD, DPhil, FRCPC]

Author Disclosures

      1. Neal S. Parikh, MD, MS,
      2. Daniel Restifo, MS,
      3. Aravind Ganesh, MD, DPhil, FRCPC and
      4. Hooman Kamel, MD, MS
    1. Neal S. Parikh, MD, MS,
      2. Scientific Advisory Boards:

      1. None

      Gifts:

      1. NONE

      Funding for Travel or Speaker Honoraria:

      1. None

      Editorial Boards:

      1. Stroke, Editorial Board member, 2019

      Patents:

      1. NONE

      Publishing Royalties:

      1. NONE

      Employment, Commercial Entity:

      1. NONE

      Consultancies:

      1. NONE

      Speakers' Bureaus:

      1. NONE

      Other Activities:

      1. Medicolegal consulting/expert witness work.

      Clinical Procedures or Imaging Studies:

      1. NONE

      Research Support, Commercial Entities:

      1. NONE

      Research Support, Government Entities:

      1. NIH/NIA K23AG073524, PI, 2021-2026; New York State Empire <br>Clinical Research Investigator Program, <br>Fellow, 2020-2021.

      Research Support, Academic Entities:

      1. NONE

      Research Support, Foundations and Societies:

      1. Leon Levy Foundation Fellowship in Neuroscience; Florence <br>Gould Foundation Endowment for Discovery in Stroke.

      Stock/Stock Options/Board of Directors Compensation:

      1. NONE

      License Fee Payments, Technology or Inventions:

      1. NONE

      Royalty Payments, Technology or Inventions:

      1. NONE

      Stock/Stock Options, Research Sponsor:

      1. NONE

      Stock/Stock Options, Medical Equipment & Materials:

      1. NONE

      Legal Proceedings:

      1. NONE

    2. Daniel Restifo, MS,
      3. Scientific Advisory Boards:

      1. None

      Gifts:

      1. NONE

      Funding for Travel or Speaker Honoraria:

      1. None

      Editorial Boards:

      1. NONE

      Patents:

      1. NONE

      Publishing Royalties:

      1. NONE

      Employment, Commercial Entity:

      1. NONE

      Consultancies:

      1. NONE

      Speakers' Bureaus:

      1. NONE

      Other Activities:

      1. NONE

      Clinical Procedures or Imaging Studies:

      1. NONE

      Research Support, Commercial Entities:

      1. NONE

      Research Support, Government Entities:

      1. NONE

      Research Support, Academic Entities:

      1. NONE

      Research Support, Foundations and Societies:

      1. None

      Stock/Stock Options/Board of Directors Compensation:

      1. NONE

      License Fee Payments, Technology or Inventions:

      1. NONE

      Royalty Payments, Technology or Inventions:

      1. NONE

      Stock/Stock Options, Research Sponsor:

      1. NONE

      Stock/Stock Options, Medical Equipment & Materials:

      1. NONE

      Legal Proceedings:

      1. NONE

    3. Aravind Ganesh, MD, DPhil, FRCPC and
      4. Scientific Advisory Boards:

      1. None

      Gifts:

      1. NONE

      Funding for Travel or Speaker Honoraria:

      1. (1) University of Calgary Post-Graduate Medical Education <br>(PGME): travel funding for conferences<br>(2) American Academy of Neurology: Futures in Neurological <br>Research award, resident scholarships, International <br>Scholar award<br>(3) Alexion: honoraria for educational presentation

      Editorial Boards:

      1. (1) Neurology Editorial Board, Disputes and Debates, 2018-<br>Present<br>(2) Neurology: Clinical Practice Editorial Board, Practice <br>Current, 2019-Present<br>(3) Stroke, Editorial Board Member, 2019-present<br>(4) Frontiers in Neurology, Editorial Board Member, 2021

      Patents:

      1. Patent application (US 17/317,771) for a system <br>for patient monitoring and delivery of remote ischemic <br>conditioning or other cuff-based therapies.

      Publishing Royalties:

      1. NONE

      Employment, Commercial Entity:

      1. NONE

      Consultancies:

      1. (1) MD Analytics: honoraria for research consultation<br>(2) My Medical Panel: honoraria for research consultation<br>(3) DeepBench: honoraria for research consultation<br>(4) Research On Mind: honoraria for research consultation<br>(5) Figure 1: honoraria for educational consultation<br>(6) CTC Communications Corporation: honoraria for <br>educational consultation<br>(7) Atheneum: honoraria for research consultation<br>(8) Biogen: honoraria for educational consultation

      Speakers' Bureaus:

      1. NONE

      Other Activities:

      1. NONE

      Clinical Procedures or Imaging Studies:

      1. NONE

      Research Support, Commercial Entities:

      1. NONE

      Research Support, Government Entities:

      1. Government of Canada INOVAIT program, PI, 2021-2022

      Research Support, Academic Entities:

      1. NONE

      Research Support, Foundations and Societies:

      1. (1) Alberta Innovates<br>(2) Canadian Institutes of Health Research<br>(3) Canadian Cardiovascular Society<br>(4) Campus Alberta Neuroscience<br>(5) New Frontiers in Research Fund

      Stock/Stock Options/Board of Directors Compensation:

      1. (1) SnapDx Inc.<br>(2) TheRounds.com<br>(3) Advanced Health Analytics (AHA Health Ltd)

      License Fee Payments, Technology or Inventions:

      1. NONE

      Royalty Payments, Technology or Inventions:

      1. NONE

      Stock/Stock Options, Research Sponsor:

      1. NONE

      Stock/Stock Options, Medical Equipment & Materials:

      1. NONE

      Legal Proceedings:

      1. NONE

    4. Hooman Kamel, MD, MS
      5. Scientific Advisory Boards:

      1. None

      Gifts:

      1. NONE

      Funding for Travel or Speaker Honoraria:

      1. None

      Editorial Boards:

      1. (1) Journal Watch Neurology, Associate Editor, 2011-2016.<br>(2) PLOS One, Academic Editor, 2013-2016<br>(3) Scientific Reports, Editorial Board Member, 2014-<br>2016.<br>(4) JAMA Neurology, Deputy Editor, 2017-current.

      Patents:

      1. NONE

      Publishing Royalties:

      1. NONE

      Employment, Commercial Entity:

      1. NONE

      Consultancies:

      1. Has served on a one-time advisory board for Roivant <br>Sciences related to Factor XI inhibition (2018).

      Speakers' Bureaus:

      1. (1) Speakers bureau for Genentech, Inc., 2012-2016

      Other Activities:

      1. (1) Steering Committee of Medtronic's Stroke AF trial <br>(uncompensated).<br>(2) Stroke endpoint adjudication committee for diabetes-<br>related drug for Boehringer-Ingelheim.<br>(3) Executive Committee for a Janssen trial.

      Clinical Procedures or Imaging Studies:

      1. NONE

      Research Support, Commercial Entities:

      1. Dr. Kamel serves as co-PI for the NIH-funded ARCADIA <br>trial (NINDS U01NS095869) which receives in-kind study <br>drug from the BMS-Pfizer Alliance for Eliquis&#x00AE; and <br>ancillary study support from Roche Diagnostics.

      Research Support, Government Entities:

      1. (1) NIH/NINDS, K23NS082367, 2013-current.<br>(2) NIH/NINDS, R01NS097443, 2016-2021.<br>(3) NIH/NINDS, U01NS095869, 2016-current.<br>(4) NIH/NINDS, R01HL144541, 2019-current.

      Research Support, Academic Entities:

      1. Dr. Kamel serves as a PI for the NIH-funded ARCADIA trial <br>(NINDS U01NS095869), which receives in-kind study drug from <br>the BMS-Pfizer Alliance for Eliquis&#x00AE; and ancillary study <br>support from Roche Diagnostics; as Deputy Editor for JAMA <br>Neurology; on clinical trial steering/executive committees <br>for Medtronic, Janssen, and Javelin Medical; and on endpoint <br>adjudication committees for Novo Nordisk and Boehringer <br>Ingelheim.

      Research Support, Foundations and Societies:

      1. (1) Michael Goldberg Stroke Research Fund, 2014

      Stock/Stock Options/Board of Directors Compensation:

      1. NONE

      License Fee Payments, Technology or Inventions:

      1. NONE

      Royalty Payments, Technology or Inventions:

      1. NONE

      Stock/Stock Options, Research Sponsor:

      1. NONE

      Stock/Stock Options, Medical Equipment & Materials:

      1. NONE

      Legal Proceedings:

      1. NONE

    1. Clinical and Translational Neuroscience Unit (NSP, DR, HK), Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York City; and Department of Clinical Neurosciences (AG), University of Calgary, Alberta, Canada.
    1. Correspondence
      Dr. Parikh nsp2001{at}med.cornell.edu
    View Full Text

    Article usage

    Article usage: January 2023 to August 2023

    AbstractFullPdfSource
    Jan 2023316197Highwire
    Feb 20231371818Highwire
    Mar 2023170118Highwire
    Apr 20239521Highwire
    May 202310210Highwire
    Jun 20237444Highwire
    Jul 20237032Highwire
    Aug 20234941Highwire

    The Nerve!: Rapid online correspondence

    No comments have been published for this article.
    Comment

    REQUIREMENTS

    You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

    Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

    If you are responding to a comment that was written about an article you originally authored:
    You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
    and apply to letter.

    Submission specifications:

    • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
    • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
    • Submit only on articles published within 6 months of issue date.
    • Do not be redundant. Read any comments already posted on the article prior to submission.
    • Submitted comments are subject to editing and editor review prior to posting.

    More guidelines and information on Disputes & Debates

    Compose Comment

    More information about text formats

    Plain text

    • No HTML tags allowed.
    • Web page addresses and e-mail addresses turn into links automatically.
    • Lines and paragraphs break automatically.
    Author Information
    NOTE: The first author must also be the corresponding author of the comment.
    First or given name, e.g. 'Peter'.
    Your last, or family, name, e.g. 'MacMoody'.
    Your email address, e.g. higgs-boson@gmail.com
    Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
    Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
    Publishing Agreement
    NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

    Vertical Tabs

    You May Also be Interested in

    Back to top
    Advertisement

    Related Articles

    • No related articles found.

    Alert Me